Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Non-Current Assets (2022 - 2025)

Historic Non-Current Assets for NewAmsterdam Pharma (NAMS) over the last 4 years, with Q3 2025 value amounting to $54.1 million.

  • NewAmsterdam Pharma's Non-Current Assets rose 400774.49% to $54.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $101.7 million, marking a year-over-year increase of 272279.29%. This contributed to the annual value of $1.2 million for FY2024, which is 29444.44% up from last year.
  • NewAmsterdam Pharma's Non-Current Assets amounted to $54.1 million in Q3 2025, which was up 400774.49% from $45.3 million recorded in Q2 2025.
  • NewAmsterdam Pharma's Non-Current Assets' 5-year high stood at $89.1 million during Q2 2023, with a 5-year trough of $306000.0 in Q4 2023.
  • Over the past 4 years, NewAmsterdam Pharma's median Non-Current Assets value was $1.3 million (recorded in 2024), while the average stood at $28.0 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first tumbled by 9964.06% in 2023, then skyrocketed by 400774.49% in 2025.
  • Over the past 4 years, NewAmsterdam Pharma's Non-Current Assets (Quarter) stood at $85.1 million in 2022, then plummeted by 99.64% to $306000.0 in 2023, then skyrocketed by 294.44% to $1.2 million in 2024, then surged by 4382.1% to $54.1 million in 2025.
  • Its last three reported values are $54.1 million in Q3 2025, $45.3 million for Q2 2025, and $1.1 million during Q1 2025.